Quarterly Performance Reviews, Dividends, and Legal Updates - Research Reports on T. Rowe, BB&T, Teva, HCA Holdings and Boston Scientific

NEW YORK, August 13, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding T. Rowe Price Group, Inc. (NASDAQ: TROW), BB&T Corporation (NYSE: BBT), Teva Pharmaceutical Industries Limited (NYSE: TEVA), HCA Holdings, Inc. (NYSE: HCA) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5696-100free.

--
T. Rowe Price Group, Inc. Research Reports
On July 24, 2014, T. Rowe Price Group, Inc. (T. Rowe) announced its Q2 2014 financial results. The Company's net revenue during the quarter increased 15.2% YoY to $984.3 million. Investment advisory revenues of the Company rose 15.6% YoY to $855.3 million, as average assets under management (AUM) increased $92.1 billion. During the quarter, market appreciation and income of $27.2 billion, offset slightly by net cash outflows from investors of $200 million, lifted Company's AUM to a record $738.4 billion at June 30, 2014. Net income attributable to common shareholders increased to $302.4 million or $1.13 per diluted share, compared with $245.8 million, or $0.92 per diluted share, in Q2 2013. On average, analysts polled by Bloomberg expected the Company's net income per share at $1.12. The full research reports on T. Rowe are available to download free of charge at:

http://www.analystsreview.com/Aug-13-2014/TROW/report.pdf

--
BB&T Corporation Research Reports
On July 22, 2014, BB&T Corporation (BB&T) announced that its Board of Directors has declared the following quarterly dividends: $0.24 per share on BB&T's common stock; $365.625 per share on BB&T's Series D Non-Cumulative Perpetual Preferred Stock; $351.5625 per share on BB&T's Series E Non-Cumulative Perpetual Preferred Stock; $325.000 per share on BB&T's Series F Non-Cumulative Perpetual Preferred Stock; and $325.000 per share on BB&T's Series G Non-Cumulative Perpetual Preferred Stock. The Company said that these quarterly dividends are payable on September 2, 2014, to shareholders of record at the close of business on August 8, 2014. The full research reports on BB&T are available to download free of charge at:

http://www.analystsreview.com/Aug-13-2014/BBT/report.pdf

--
Teva Pharmaceutical Industries Limited Research Reports
On August 7, 2014, Teva Pharmaceutical Industries Limited (Teva) confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE® 40 mg/mL product from Dr. Reddy's Laboratories, Inc. (Dr. Reddy's). The Company stated that it will continue to defend its COPAXONE® intellectual property rights against infringement, wherever challenged. Teva plans to file a lawsuit for patent infringement against Dr. Reddy's within 45 days, which will trigger a 30 month stay of FDA approval of Dr. Reddy's ANDA. Teva informed that COPAXONE® 40 mg/mL is protected by two Orange Book patents expiring in 2030. The full research reports on Teva are available to download free of charge at:

http://www.analystsreview.com/Aug-13-2014/TEVA/report.pdf

--
HCA Holdings, Inc. Research Reports
On August 8, 2014, the stock of HCA Holdings, Inc. (HCA) declined 0.13% to end the trading session at $67.13. During the session, the stock opened at $67.21, and fluctuated in the range of $65.85 - $67.72, with a total of 3.35 million shares changing hands. Over the last one month, the Company's stock has increased by 22.17%, outperforming the Dow Jones Industrial Average, which declined 2.54% during the same period. The full research reports on HCA Holdings are available to download free of charge at:

http://www.analystsreview.com/Aug-13-2014/HCA/report.pdf

--
Boston Scientific Corporation Research Reports
On July 30, 2014, Bloomberg reported that Boston Scientific Corporation (Boston Scientific) has won the first case to go trial over its vaginal-mesh devices. According to the report, a jury in state court in Massachusetts rejected Diane Albright's claims that the mesh's faulty design caused her injuries and found that the Company's officials had adequately warned Albright of device's risks. Bloomberg stated that the verdict is first in more than 12,000 lawsuits in which women have charged the Company of making vaginal-mesh devices that ends up causing organ damage and pain. The full research reports on Boston Scientific are available to download free of charge at:

http://www.analystsreview.com/Aug-13-2014/BSX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED